AMRX (Amneal Pharmaceuticals) Current Accrued Expense: $407 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMRX Amneal Pharmaceuticals Inc AMRX
59 GF Score
Price $17.91
GF Value $8.18
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Amneal Pharmaceuticals Current Accrued Expense?

Amneal Pharmaceuticals AMRX +0.06% 59 Current Accrued Expense is $407 Mil as of Jun. 2026. GuruFocus rates AMRX with a GF Score™ of 59/100 and a GF Value™ of $8.18 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Amneal Pharmaceuticals's Current Accrued Expense for the quarter that ended in Jun. 2026 was $407 Mil.

Amneal Pharmaceuticals's quarterly Current Accrued Expense declined from Dec. 2025 ($427 Mil) to Mar. 2026 ($381 Mil) but then increased from Mar. 2026 ($381 Mil) to Jun. 2026 ($407 Mil).

Amneal Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2023 ($310 Mil) to Dec. 2024 ($404 Mil) and increased from Dec. 2024 ($404 Mil) to Dec. 2025 ($427 Mil).

Amneal Pharmaceuticals Current Accrued Expense Related Terms

Amneal Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Amneal Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amneal Pharmaceuticals Current Accrued Expense Chart

Amneal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 319.41 307.96 309.74 403.80 426.76

Amneal Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 393.77 391.34 426.76 381.03 407.30
AMRX
59GF Score
Amneal Pharmaceuticals Inc AMRX
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amneal Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $407 Mil mean?
Amneal Pharmaceuticals (AMRX) has a Current Accrued Expense of $407 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Amneal Pharmaceuticals and its competitors.
Is Amneal Pharmaceuticals' Current Accrued Expense too high?
Amneal Pharmaceuticals' current Current Accrued Expense is $407 Mil. Overall, Amneal Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' Current Accrued Expense compare to HIMS and KNSA?
Amneal Pharmaceuticals' Current Accrued Expense of $407 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Amneal Pharmaceuticals and its competitors. Amneal Pharmaceuticals's current Current Accrued Expense is $407 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $8.18, compared to a current price of $17.91 — trading 118.9% above its estimated fair value. The current Current Accrued Expense is $407 Mil. Amneal Pharmaceuticals' overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current Current Accrued Expense is $407 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of $17.91 is trading 118.9% above its estimated GF Value™ of $8.18. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for AMRX:

  • Current Accrued Expense: $407 Mil
  • GF Value™: $8.18 vs. price of $17.91 (118.9% above fair value)
  • GF Score™: 59/100 with 7 warning signs

No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amneal Pharmaceuticals Business Description

Other Exchanges 2DT:Germany
Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
59GF Score

Get the complete analysis for AMRX

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.91
Price
$8.18
GF Value